ArticleEndocrine oncology (Bristol, England)2026
Clinical application of digital pathology in small intestinal neuroendocrine tumours: proposal of a new G0 category.
Article in Endocrine oncology (Bristol, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Small intestinal neuroendocrine tumours (siNETs) are usually indolent neoplasms, most of which are classified as grade 1 with very low proliferative activity. In practice, Ki-67 in G1 siNETs is often reported simply as '<3%', limiting prognostic discrimination. Digital pathology now enables reliable automated quantification of very low Ki-67 values. We investigated whether precise Ki-67 quantification could improve prognostic stratification in G1 siNETs. Methods: We retrospectively included 63 consecutive patients who underwent surgery for a G1 siNET at Beaujon Hospital between 2001 and 2017. Ki-67 was quantified on primary tumours (PTs) and, when available, lymph node and liver metastases, using QuPath automated image analysis. Ki-67 was assessed in the highest-proliferation hotspot (0.4 mm Results: Among 63 patients, 33 underwent curative-intent surgery (median age: 56 years; 69% male). Median tumour size was 20 mm. At surgery, 87% were node-positive and 67% had synchronous metastases. Median Ki-67 Conclusion: Precise digital Ki-67 quantification refines prognostic stratification in G1 siNETs. Tumours with Ki-67 <1% may represent a biologically distinct 'G0' subgroup associated with extremely low recurrence risk after curative surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.